Biologic Therapeutic Drugs: Technologies and Global Markets
Report Highlights
The global market for biologic therapeutic drugs should increase from $285.5 billion in 2020 to reach $421.8 billion by 2025, at a compound annual growth rate (CAGR) of 8.1% during the forecast period of 2020-2025.
Report Includes
- 22 data tables and 26 additional tables
- An overview of the global market for biologic therapeutic drugs
- Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of market size and market forecast; and detailed review of drivers, challenges, and opportunities affecting the global market growth
- Detailed description of product segments of biologic therapeutic drugs, such as therapeutic proteins, vaccines, cell therapy, gene therapy, blood plasma products, and others
- Assessment of the competitive environment, with a special focus on how new products and technologies are influencing the current standards of care
- Country specific data and analysis for the United States, Canada, Germany, U.K., France, Italy, Spain, Russia, China, India, Japan and other emerging economies
- Impact analysis of COVID-19 on the entire life sciences industry as well as on biologic therapeutic drugs market
- Profiles of current market leaders, as well as companies with innovative products poised to advance within the forecast period
- Company profile descriptions of major biologic therapeutic drugs manufacturers, including Amgen Inc., Baxter International, CSL Ltd., Eli Lilly and Co., F. Hoffmann-La Roche, GlaxoSmithKline Plc, Novartis and Sanofi
Report Scope
The current report offers a detailed picture of the biologics market.
This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2025, as well as key market players.
This report details market shares for biologics based on product and geography. Based on product, the market is segmented into therapeutic proteins, vaccines and other segments.
Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2020 as the base year, with forecasts for 2020 through 2025. Estimated values are based on product manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Mental Health Application: Technologies and Global Markets (HLC293A)
- Global Bioanalytical Testing Services Market (BIO247A)
- Microelectromechanical Systems (MEMS) Technology: Current and Future Markets (SMC051E)
- Global Abrasive Market: Materials, Products, and Applications (AVM033E)
- Hydraulic Pumps and Motors: Global Markets (MFG034C)
Report Highlights
The global biologics market totaled $200.6 billion in 2013 and is expected to grow to nearly $234 billion in 2014. The total market is expected to grow to $386.7 billion by the end of 2019 at compound annual growth rate (CAGR) of 10.6%.
Report Includes
- An overview of the global market for biologic therapeutic drugs
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019
- Coverage of large market segments such as monoclonal antibodies (mAb), therapeutic proteins, and vaccines
- Examination of the competitive environment with a special focus on how new products and technologies are influencing the current standard of care
- Comprehensive profiles of current market leaders, as well as companies with innovative products poised to advance within the forecast period.
Report Highlights
The market for biologics was valued at $150 billion in 2011 and should reach $163 billion in 2012. Total market value is expected to reach $252 billion in 2017 after increasing at a five-year compound annual growth rate of 9%.
Report Includes
- An overview of the global market for biologic therapeutic drugs
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Coverage of large market segments such as monoclonal antibodies (mAb), therapeutic proteins, and vaccines
- Examination of the competitive environment with a special focus on how new products and technologies are influencing the current standard of care
- Comprehensive profiles of current market leaders, as well as companies with innovative products poised to advance within the forecast period.
Report Highlights
The global biologics market is valued at an estimated $149 billion in 2010 and is expected to reach $239 billion by 2015, a compound annual growth rate (CAGR) of 9.9% from 2010-2015. Driving this growth is the need for a more extensive drug pipeline, attractive targets against challenging diseases, a push to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.